systematic review is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
=== Central & East Indo-Pacific === 2024 Vietnamese export of pangasius maw has increased to about US$58,000,000, with 38% going to China and the rest to Thailand, Malaysia, Singapore and the USA. The Vietnam News Agency claims that the falling totoaba population has incentivized Chinese import of alternative maw. The island and seas of New Guinea see significant fish maw production. Since 2012, in and around the Kikori River delta of Papua New Guinea, the scaly croaker Nibea squamosa has been targeted in gillnetting for its extremely high-priced maw, selling for as much as US$15,615 per kilogram.
During the late 18th and early 19th centuries, patients undergoing surgery were often administered laudanum and alcohol, and had their hands restrained and bodies held down while the operation was performed.
This use a treatment for disease was pioneered in 1890 by Emil von Behring and Shibasaburo Kitasato, who first demonstrated that the endotoxin from the infectious diseases diphtheria and tetanus could be used to prevent or cure non-immunized animals using serum transfusions from an immune animal to a susceptible one. Building on in this logic, and at the same session of the Society of Biology in Paris on February 10, 1894, Albert Calmette at the Pasteur Institute and independently Césaire Phisalix and Gabriel Bertrand at the Department of Pathology and Chemistry in the National Museum of National History in France, announced that they had achieved treatment of a vulnerable animal with serum from an immunized one both using snake venom. Calmette went on subsequently to immunize horses using venom from Indian cobras, and the resulting Serum Antivenimeux (antivenomous serum) became the first commercially available antivenom product. In 1895 Sir Thomas Fraser, Professor of Medicine at the University of Edinburgh, also produced a serum to act against cobra venom. His "antivenene" was effective in the laboratory. In 1901, Vital Brazil, working at the Instituto Butantan in São Paulo, Brazil, developed the first monovalent and polyvalent antivenoms for Central and South American Crotalus and Bothrops snakes, as well as for certain species of venomous spiders, scorpions, and frogs. In Mexico in 1905, Daniel Vergara Lope developed an antivenom against scorpion venom, by immunizing dogs. In Australia, the Commonwealth Serum Laboratories (CSL) began antivenom research in the 1920s.
Andrés de Santa Cruz, who would have had apparent contradictions in his geopolitical projects, due to a highland nationalism, in which he wanted both the reunification of Upper and Lower Peru (in a similar way to the Inca Empire or the Viceroyalty of Peru) as well as to consider dividing Peru into 2 states, one from the north and the other from the south, for the benefit of Bolivia's interests (in addition to recovering the territory of Arica for the benefit of Bolivia), which he envisioned as the "Macedonia of America" and which should have a leadership in the continent, to the detriment of the historical preponderance of Lima and Cuzco as poles of power."When he felt strong, his dreams of power were those of those legendary Incas who descended from the mountains to bring peace, order, and progress to the coast. Then he opened himself to the ideal of 'pan-Peru', of Greater Peru. Bolivia would be the "Macedonia of America". If they beat and humiliated him and cornered him on the plateau, he wanted, not so much for revenge as for security reasons, next to Bolivia, a divided or impotent Peru. His maximum program was a strong Greater Peru and extensive, that is, the Confederation, with him as head. His minimum program was to govern Bolivia, but, at his side, the bifurcation of Peru into two states and the possible fall of the South State under Bolivia's sphere of influence Such is the explanation of his political behavior until 1839.
Sources: en.wikipedia.org
Since the tight control of enzyme activity is essential for homeostasis, any malfunction (mutation, overproduction, underproduction or deletion) of a single critical enzyme can lead to a genetic disease. The malfunction of just one type of enzyme out of the thousands of types present in the human body can be fatal. An example of a fatal genetic disease due to enzyme insufficiency is Tay–Sachs disease, in which patients lack the enzyme hexosaminidase. One example of enzyme deficiency is the most common type of phenylketonuria. Many different single amino acid mutations in the enzyme phenylalanine hydroxylase, which catalyzes the first step in the degradation of phenylalanine, result in build-up of phenylalanine and related products. Some mutations are in the active site, directly disrupting binding and catalysis, but many are far from the active site and reduce activity by destabilising the protein structure, or affecting correct oligomerisation. This can lead to intellectual disability if the disease is untreated. Another example is pseudocholinesterase deficiency, in which the body's ability to break down choline ester drugs is impaired. Oral administration of enzymes can be used to treat some functional enzyme deficiencies, such as pancreatic insufficiency and lactose intolerance. Another way enzyme malfunctions can cause disease comes from germline mutations in genes coding for DNA repair enzymes. Defects in these enzymes cause cancer because cells are less able to repair mutations in their genomes.
Stromelysin-1 also known as matrix metalloproteinase-3 (MMP-3) is an enzyme that in humans is encoded by the MMP3 gene. The MMP3 gene is part of a cluster of MMP genes which localize to chromosome 11q22.3. MMP-3 has an estimated molecular weight of 54 kDa.
== Reproduction == Most cone snails appear to reproduce sexually, with separate sexes and internal fertilization. Varying numbers of eggs in egg capsules are laid in substrate by cone snails. Hatchlings are of two types, the veligers (larvae that swim freely) and veliconcha (baby snail).
The Italian government, presided over by Emilio Colombo after the resignation of Mariano Rumor, appealed to the people of Reggio Emilia to end the violence. Otherwise, it promised the use of force. For the first time in the history of the Italian Republic, the government sent in the army and carabinieri. Even far-left parties, including the Communists and the PSIUP, condemned the uprising, decrying it as parochial and non-proletarian, often clashing with their own voter base. On 23 February 1971, after 10 months of rioting, the revolt ceased given a compromise with the regional government. The Prime Minister, meeting with the president of the Calabria Region, Antonio Guarasci (CD), and regional politicians of various parties, assembled the Colombo Package, which sought to involve all parties: Catanzaro would be the regional capital, while Reggio would host the regional council; Cosenza would be the site of Calabria's first university (University of Calabria), while Gioia Tauro would become the fifth national steel hub and a chemical factory would be established in Saline Joniche. The agreement was accepted by the populace, but the steel plant was never built, while the chemical plant, although built, ceased production almost immediately due to Ministry of Health provisions that declared the feedstocks it produced to be carcinogenic. In the 1972 general elections the scales shifted in favor of the right, which won 27% of the vote and became the leading party in Reggio and Ciccio Franco was elected to the Senate.
On 16 and 17 June 2025, the governments of Greenland, Denmark, and the Faroe Islands participated in their biannual meeting in Tórshavn in light of the crisis. While Danish prime minister Mette Frederiksen didn't want to elaborate on her negotiations with Greenland and the Faroe Islands at the time, she called for unity among all three governments of the Kingdom of Denmark, with Faroese PM Aksel V. Johannesen calling for more foreign policy autonomy for the Faroe Islands. In response to US threats against Greenland and the Kingdom of Denmark, Prime Minister Mette Frederiksen reminded Trump that an attack on the Kingdom of Denmark is an attack on NATO and that all members are obligated to come to Denmark's defence, urging the US to cease its threats, which threaten the existence of NATO and the security framework established since the end of World War II. The official Danish threat assessment published by the Danish Defence Intelligence Service in 2025 for the first time mentioned the US as a threat to national security, alongside Russia and China. In response to American influence operations, both Prime Minister Mette Frederiksen and King Frederik X visited the Danish territory. After Trump resumed his threats in December 2025, Foreign Minister Lars Løkke Rasmussen insisted on respect for the territorial integrity of the Kingdom of Denmark.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.